The discussion panel at both the Perugia and Chicago meetings has reached a consensus regarding major aspects of the protocol of choice for haploidentical stem cell transplantation (SCT) in acute leukemia. These include specific parameters relating to patients eligibility, graft manipulation and cell composition of the final inoculum, conditioning of the patient and post-transplant treatment.
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Inclusion criteria

When to transplant
In order to reduce transplant-related mortality in high risk first remission or subsequent remission, it is recommended to apply haploidentical SCT as soon as possible, similar to the criteria employed for matched unrelated donor (MUD) transplants. The search in the MUD registries should not last for more than 3 months, preferably 2 months, and if the patient is still in complete remission after these 2-3 months and if a MUD has not been found by then, the patient can be considered as a candidate for haploidentical SCT.
Graft composition
Donor CD34 
Patient conditioning
Considering that most of the experience with adult haploidentical transplants was in patients conditioned with radiationbased protocols, this modality was recommended, although there is insufficient experience with chemotherapy-based protocols in adult recipients of haploidentical transplants. Successful experience has been documented either with a single dose 7.5 Gy or fractionated (6 × 2.2 Gy) radiation with lung shielding (4 Gy) in conjunction with fludarabine, thiotepa and rabbit antithymocyte globulins. Experience in children suggests that both radiation-or chemotherapy-based modalities lead to a similar outcome. Cytoreduction in children will be either fractionated total body irradiation (TBI), fludarabine and thiotepa or a non-TBI-based regimen, either melphalan-or busulfan-based.
As there is a fine equilibrium between the graft cell composition and the conditioning protocol, major deviations from any of the parameters might lead either to graft rejection or to severe graft-versus-host disease (GVHD).
Supportive care
No immunosuppressive treatment will be given after transplantation for prophylaxis against GVHD.
Patients are treated in isolation rooms with laminar airflow or high-efficiency air particle filtration. All patients receive prophylactic trimethoprim-sulfamethoxazole for Pneumocystis carinii, ciprofloxacin for selective gut decontamination and total parenteral nutrition in case of insufficient food intake. Anti-fungal prophylaxis includes itraconazole oral solution during the first 4 months post-transplant.
In recipients who are seropositive for cytomegalovirus (CMV) antibody, CMV prophylaxis consists of ganciclovir before stem cell infusion. After transplantation, prophylaxis is continued for 3-4 weeks with foscarnet and thereafter frequent CMV PCR is used for monitoring. In the case of evidence of CMV activation, patients will be treated with ganciclovir.
